EDE approves MIMRYLO for polycythemia vera, UAE becomes 2nd global market

Emirates Drug Establishment (EDE) has approved MIMRYLO (rusfertide) for adults with polycythemia vera, making the UAE the second country globally to authorise the medicine, according to Khaleej Times coverage published on 30 September 2026.

The approval matters first for Dubai haematology clinics, hospital pharmacies and payers. Polycythemia vera causes excess red blood cell production, which can thicken blood and increase clot, stroke and heart attack risk. The operational question is narrow: which eligible patients move from repeated therapeutic phlebotomy to a weekly injectable medicine, and who pays for it?

What EDE approved

EDE said MIMRYLO helps lower red blood cell levels in adults with polycythemia vera. The medicine is supplied in single-dose vials as a sterile powder that must be reconstituted before use. EDE said it should be used under the supervision of a healthcare provider experienced in managing the condition.

“The approval reflects the establishment’s commitment to helping patients access advanced treatments through a scientific assessment process that prioritises their safety.” Dr Fatima Al Kaabi, Director General, Emirates Drug Establishment

The US Food and Drug Administration approved MIMRYLO on 28 August 2026 for erythrocytosis in adults with polycythemia vera. The US prescribing information describes rusfertide as a hepcidin mimetic. It limits iron available for red blood cell production. The starting dose in the US label is 19 mg once weekly, with a weekly dose range of 9.5 mg to 108 mg. Doses above 54 mg require two injections.

What clinics and payers need to decide

Dubai providers regulated by the Dubai Health Authority (DHA) should treat the approval as a formulary and workflow issue, rather than a simple prescription change. Haematologists will need criteria for patients with uncontrolled haematocrit, recurrent phlebotomy requirements, or poor tolerance of blood removal. Pharmacy teams will need cold-chain, reconstitution and wastage procedures if local supply follows the single-dose vial format described by EDE.

In Abu Dhabi and Al Ain, the Department of Health Abu Dhabi (DOH) and payers such as Daman and Thiqa will shape access through coding, prior authorisation and network pharmacy rules. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, providers licensed by the Ministry of Health and Prevention (MOHAP) should check whether the product is visible in UAE medicine registration and local procurement channels before scheduling patients.

• Eligibility: adults with polycythemia vera; paediatric use was not included in the EDE announcement.
• Administration: weekly subcutaneous dosing in the US label, with reconstitution before injection.
• Monitoring: the US label calls for complete blood count monitoring every 2 to 4 weeks during dose changes.
• Target: the US label refers to maintaining haematocrit below 45%, a threshold operators can use when building protocols.

The UAE announcement did not state local launch timing, list price or insurance coverage. Clinics should ask Takeda’s UAE distributor or medical team for the registered UAE price, then confirm reimbursement with each insurer. For Dubai plans, that means checking policy wording and pharmacy benefits with payers such as Sukoon. For Abu Dhabi patients, Daman and Thiqa coverage will depend on benefit design and medical necessity rules.

Why patients may ask for it

Therapeutic phlebotomy can require repeat visits, laboratory checks and appointment slots. MIMRYLO may reduce that burden for eligible adults if local access is granted. Takeda said clinical trials showed control of red blood cell levels, fewer blood-removal procedures and improvement in fatigue, according to Khaleej Times.

The commercial impact will be modest in volume because polycythemia vera is rare. The per-patient impact may still be material. A weekly specialty injectable can move cost from procedure billing into pharmacy benefit spend. CFOs should compare the annual cost of current phlebotomy visits, complete blood count testing and consultant follow-up against the net reimbursed medicine cost once UAE pricing is available.

Medical directors should also treat this as a consent and safety issue. The FDA label lists warnings including increased platelet counts and malignancy risk monitoring. UAE clinicians should use the locally approved product information when it is available, document why the patient meets criteria, and keep follow-up intervals explicit.

For licensed dispensing options, operators and patients can review the UAE Open Healthcare Directory to identify pharmacy providers, then verify licence status with DHA, DOH Abu Dhabi or MOHAP before dispensing or referral.